Акушерство и Гинекология Санкт-Петербурга. 2020; : 18-22
Протоколы и клиническая практика профилактики рака шейки матки в подростковом возрасте
Аннотация
В статье обобщены литературные данные о распространенности, естественном течении папилломавирусной инфекции (ПВИ) шейки матки, приведены международные и российские клинические рекомендации по профилактике рака шейки матки (РШМ) у подростков. Представлен клинический случай и проанализирована тактика ведения 16-летней пациентки с цервикальной ПВИ. На основании представленного материала сделан вывод о том, что особенности течения инфекции, вызванной вирусом папилломы человека (ВПЧ), в подростковой возрастной группе делают целесообразной тактику откладывания цитологического скрининга РШМ до возраста 21 год (или через три года от начала половой жизни), а ВПЧ-тестирования – до 30 лет.
Список литературы
1. Гордеев С.С. ВПЧ-ассоциированные заболевания в практике онкопроктолога. Эпидемиология и Вакцинопрофилактика. 2018; 17 (5): 106–110. doi: 10.31631/2073-3046-2018-17-5-106-110.
2. Прилепская В.Н., Зардиашвили М.Д., Хлебкова Ю.С., Некрасова М.Е. Вакцинация против ВПЧ-ассоциированных заболеваний и рака шейки матки: теоретические и практические аспекты. Медицинский совет. 2016; 12: 120–125.
3. Plummer M., de Martel C., Vignat J. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4 (9): e609–616. doi: 10.1016/S2214- 109X(16)30143-7.
4. Голованова В.А. Значение инфицированности вирусом папилломы человека в возникновении дисплазии шейки матки у девочек-подростков: Автореф. дисс. … канд. мед. наук. СПб.; 1998: 23.
5. Winer R.L., Feng Q., Hughes J.P. et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis. 2008; 197: 279. doi: 10.1086/524875.
6. Spiryda L.B. et al. Delaying Pap Test Screening in the Adolescent Population: An Evidence-Based Approach. J Pediatr Adolesc Gynecol. 2014; 27: 3–5. doi: 10.1016/j.jpag.2013.03.008.
7. Sehnal B., Rozsypal H., Nipčová M., Sláma J. The prevalence, incidence, persistence and transmission ways of human papillomavirus infection (HPV). Epidemiol Mikrobiol Imunol. 2017; 66 (4): 198–209. Pubmed.
8. Абакарова П.Р., Прилепская В.Н. ВПЧ-ассоциированные заболевания шейки матки. Возможности комплексной терапии. Гинекология. 2017; 5: 4–9. doi: 10.26442/2079-5696_19.5.4-9.
9. Bosh F.X. et al. Epidemiology and natural history of human papillomavirus infection and time-specific implications in cervical neoplasia. Vaccine. 2008; 25 (10): K1–K16. doi: 10.1016/j.vaccine.2008.05.064.
10. Moscicki A.B., Cox J.T. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010; 14: 73. doi: 10.1097/lgt.0b013e3181cec411.
11. Brown D.R. et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis. 2005; 191: 182–192. doi: 10.1086/426867. Epub 2004 Dec 10.
12. Winer R.L., Lee S.K., Hughes J.P. et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157: 218. doi: 10.1093/ajekwf180.
13. Syrjanen K. et al. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda system. Obstet. Gynecol. 1992; 79: 675. Pubmed.
14. Castle P.E., Cox J.T., Jeronimo J. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL triage study (ALTS). Obstet Gynecol. 2008; 111: 847–56. doi: 10.1097/AOG.0b013e318168460b.
15. Smith R.A., Mettlin C.J., Davis K.J., Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2000; 50: 34–49. doi: 10.3322/canjclin.50.1.34.
16. Henderson J.T., Saraiya M., Martinez G., Harper C.C., Sawaya G.F. Changes to cervical cancer prevention guidelines: effects on screening among U.S. women ages 15–29. Prev Med. 2013; 56: 25–9. doi.org/10.1016/j.ypmed.2012.10.025.
17. ACOG Practice Bulletin №131. Screening for cervical cancer. Obstet Gynecol. 2012; 120: 1222–38. doi: 10.1097/aog.0b013e318277c92a.
18. Roland K., Benard V., Soman A. et al. Cervical cancer screening among women ages 18–29 in the United States. Cancer Epidemiol Biomarkers Prev. 2013; 22 (4) April. doi: 10.1158/1055-9965.EPI-12-1266.
19. Адамян Л.В. Доброкачественные и предраковые заболевания шейки матки с позиции профилактики рака. Клинические рекомендации (протоколы диагностики и ведения больных). М.; 2017.
20. Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516. doi: 10.3322/caac.21139.
21. Haugsdal M.L., Ryan G.L. HPV and Cervical Dysplasia in Adolescents: A Progressive March Toward Prevention. J Pediatr Adolesc Gynecol. 2015; 28: 127-131. doi: 10.1016/j.jpag.2014.05.002.
22. Spiryda L.B. et al. Delaying Pap Test Screening in the Adolescent Population: An Evidence-Based Approach. J Pediatr Adolesc Gynecol. 2014; 27: 3–5. doi: 10.1016/j.jpag.2013.03.008.
23. Sanfilippo J.S. HPV One Two Three. J Pediatr Adolesc Gynecol. 2015; 28: 125–126. doi.org/10.1016/j.jpag.2015.04.006
24. Korkidakis A., Bryson P., Jamieson M. Outcomes of a Decade of Routine Cervical Screening in a Canadian Adolescent Obstetrics Clinic. J Obstet Gynaecol Can. 2016; 38 (1): 51–55. doi: 10.1016/j.jogc.2015.12.001.
25. Вакцинопрофилактика заболеваний, вызванных вирусом папилломы человека.: Федеральные клинические рекомендации. МЗ РФ, Союз педиатров России. М.: ПедиатрЪ; 2016. 40 с. doi: 10.15690/vsp.v16i2.1711.
26. Ульрих Е.А., Урманчеева А.Ф., Гуркин Ю.А., Семиглазова Д.В., Ульрих Д.Г., Халимбекова Д.И. и др. Первичная профилактика рака шейки матки. Эффективность, безопасность, экономическая приемлемость вакцинации. Онкогинекология. 2018; 4 (28): 61.
Obstetrics and Gynaecology of Saint-Petersburg. 2020; : 18-22
Protocols and clinical practice for cervical cancer prevention in adolescence
Abstract
The article summarizes the literature data on the prevalence and natural course of human papillomavirus infection (HPV) of the cervix, provides international and Russian clinical guidelines for the prevention of cervical cancer (CC) in adolescents. A clinical case of a 16-year-old patient with cervical HPV is presented and analyzed. Basing on the presented material it was concluded that the specificity of HPV in the adolescent age group justifies delaying the cytological screening of cervical cancer until the age of 21 (or three years after the onset of sexual activity), and HPV-testing – up to 30 years.
References
1. Gordeev S.S. VPCh-assotsiirovannye zabolevaniya v praktike onkoproktologa. Epidemiologiya i Vaktsinoprofilaktika. 2018; 17 (5): 106–110. doi: 10.31631/2073-3046-2018-17-5-106-110.
2. Prilepskaya V.N., Zardiashvili M.D., Khlebkova Yu.S., Nekrasova M.E. Vaktsinatsiya protiv VPCh-assotsiirovannykh zabolevanii i raka sheiki matki: teoreticheskie i prakticheskie aspekty. Meditsinskii sovet. 2016; 12: 120–125.
3. Plummer M., de Martel C., Vignat J. et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health. 2016; 4 (9): e609–616. doi: 10.1016/S2214- 109X(16)30143-7.
4. Golovanova V.A. Znachenie infitsirovannosti virusom papillomy cheloveka v vozniknovenii displazii sheiki matki u devochek-podrostkov: Avtoref. diss. … kand. med. nauk. SPb.; 1998: 23.
5. Winer R.L., Feng Q., Hughes J.P. et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis. 2008; 197: 279. doi: 10.1086/524875.
6. Spiryda L.B. et al. Delaying Pap Test Screening in the Adolescent Population: An Evidence-Based Approach. J Pediatr Adolesc Gynecol. 2014; 27: 3–5. doi: 10.1016/j.jpag.2013.03.008.
7. Sehnal B., Rozsypal H., Nipčová M., Sláma J. The prevalence, incidence, persistence and transmission ways of human papillomavirus infection (HPV). Epidemiol Mikrobiol Imunol. 2017; 66 (4): 198–209. Pubmed.
8. Abakarova P.R., Prilepskaya V.N. VPCh-assotsiirovannye zabolevaniya sheiki matki. Vozmozhnosti kompleksnoi terapii. Ginekologiya. 2017; 5: 4–9. doi: 10.26442/2079-5696_19.5.4-9.
9. Bosh F.X. et al. Epidemiology and natural history of human papillomavirus infection and time-specific implications in cervical neoplasia. Vaccine. 2008; 25 (10): K1–K16. doi: 10.1016/j.vaccine.2008.05.064.
10. Moscicki A.B., Cox J.T. Practice improvement in cervical screening and management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010; 14: 73. doi: 10.1097/lgt.0b013e3181cec411.
11. Brown D.R. et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis. 2005; 191: 182–192. doi: 10.1086/426867. Epub 2004 Dec 10.
12. Winer R.L., Lee S.K., Hughes J.P. et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003; 157: 218. doi: 10.1093/ajekwf180.
13. Syrjanen K. et al. Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda system. Obstet. Gynecol. 1992; 79: 675. Pubmed.
14. Castle P.E., Cox J.T., Jeronimo J. An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL triage study (ALTS). Obstet Gynecol. 2008; 111: 847–56. doi: 10.1097/AOG.0b013e318168460b.
15. Smith R.A., Mettlin C.J., Davis K.J., Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2000; 50: 34–49. doi: 10.3322/canjclin.50.1.34.
16. Henderson J.T., Saraiya M., Martinez G., Harper C.C., Sawaya G.F. Changes to cervical cancer prevention guidelines: effects on screening among U.S. women ages 15–29. Prev Med. 2013; 56: 25–9. doi.org/10.1016/j.ypmed.2012.10.025.
17. ACOG Practice Bulletin №131. Screening for cervical cancer. Obstet Gynecol. 2012; 120: 1222–38. doi: 10.1097/aog.0b013e318277c92a.
18. Roland K., Benard V., Soman A. et al. Cervical cancer screening among women ages 18–29 in the United States. Cancer Epidemiol Biomarkers Prev. 2013; 22 (4) April. doi: 10.1158/1055-9965.EPI-12-1266.
19. Adamyan L.V. Dobrokachestvennye i predrakovye zabolevaniya sheiki matki s pozitsii profilaktiki raka. Klinicheskie rekomendatsii (protokoly diagnostiki i vedeniya bol'nykh). M.; 2017.
20. Saslow D., Solomon D., Lawson H.W. et al. American Cancer Society; American Society for Colposcopy and Cervical Pathology; American Society for Clinical Pathology: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012; 137: 516. doi: 10.3322/caac.21139.
21. Haugsdal M.L., Ryan G.L. HPV and Cervical Dysplasia in Adolescents: A Progressive March Toward Prevention. J Pediatr Adolesc Gynecol. 2015; 28: 127-131. doi: 10.1016/j.jpag.2014.05.002.
22. Spiryda L.B. et al. Delaying Pap Test Screening in the Adolescent Population: An Evidence-Based Approach. J Pediatr Adolesc Gynecol. 2014; 27: 3–5. doi: 10.1016/j.jpag.2013.03.008.
23. Sanfilippo J.S. HPV One Two Three. J Pediatr Adolesc Gynecol. 2015; 28: 125–126. doi.org/10.1016/j.jpag.2015.04.006
24. Korkidakis A., Bryson P., Jamieson M. Outcomes of a Decade of Routine Cervical Screening in a Canadian Adolescent Obstetrics Clinic. J Obstet Gynaecol Can. 2016; 38 (1): 51–55. doi: 10.1016/j.jogc.2015.12.001.
25. Vaktsinoprofilaktika zabolevanii, vyzvannykh virusom papillomy cheloveka.: Federal'nye klinicheskie rekomendatsii. MZ RF, Soyuz pediatrov Rossii. M.: Pediatr\"\"; 2016. 40 s. doi: 10.15690/vsp.v16i2.1711.
26. Ul'rikh E.A., Urmancheeva A.F., Gurkin Yu.A., Semiglazova D.V., Ul'rikh D.G., Khalimbekova D.I. i dr. Pervichnaya profilaktika raka sheiki matki. Effektivnost', bezopasnost', ekonomicheskaya priemlemost' vaktsinatsii. Onkoginekologiya. 2018; 4 (28): 61.
